SCHEMBL29347132

SCHEMBL29347132

CC(C)(C)OC(=O)CCCCCCCn1c(=O)n(C2CCCCNC2=O)c2ncccc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 4/20 0.37
▸ CRBN Q96SW2 4/20 0.37
▸ CNR2 P34972 4/20 0.36
▸ HTR4 Q13639 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ ATM Q13315 1/20 0.34
▸ CXCR4 P61073 2/20 0.34
▸ PSEN1 P49768 1/20 0.34
▸ PSEN2 P49810 1/20 0.34
▸ APH1B Q8WW43 1/20 0.34
▸ NCSTN Q92542 1/20 0.34
▸ APH1A Q96BI3 1/20 0.34
▸ PSENEN Q9NZ42 1/20 0.34
▸ PDE3B Q13370 1/20 0.34
▸ PDE3A Q14432 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31068578 0.89 HTR4 (0.39) DDB1CRBNCNR2HTR4KDM4E
SCHEMBL31068531 0.88 DDB1 (0.45) DDB1CRBNCNR2KDM4EALDH1A1
SCHEMBL31068572 0.77 DDB1 (0.55) DDB1CRBNCYP3A4CYP2D6CYP2C9
SCHEMBL29347155 0.76 HTR4 (0.34) DDB1CRBNHTR4ALDH1A1CXCR4
SCHEMBL29347058 0.76 ALDH1A1 (0.44) KDM4EALDH1A1CXCR4KMT2A
SCHEMBL29347124 0.76 DDB1 (0.47) DDB1CRBNHTR4KDM4EALDH1A1
SCHEMBL28649449 0.74 DDB1 (0.53) DDB1CRBNKDM4EALDH1A1
SCHEMBL29347429 0.74 DDB1 (0.48) DDB1CRBNHTR4KDM4EALDH1A1
SCHEMBL29347122 0.74 HTR4 (0.40) CNR2HTR4KDM4EALDH1A1CYP3A4
SCHEMBL29347152 0.73 HTR4 (0.32) DDB1CRBNHTR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388593-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR MITSUBISHI TANABE PHARMA CORPORATION (JP) 2025-12-25 — — US disclosed
EP-4650348-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR Mitsubishi Tanabe Pharma Corporation (JP) 2025-11-19 — — EP disclosed
WO-2024150815-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR 田辺三菱製薬株式会社 2024-07-18 — — WO disclosed
WO-2024150815-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR 田辺三菱製薬株式会社 2024-07-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388593-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR CRBN, CUL1, CBL DDB1 2368/4885CRBN 1/4885CNR2 2248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback